Drug Trial Radar · NCT04708782
Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
Last checked: Nov 19, 2026Latest source record: May 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
598
Actual
Start
Jun 1, 2021
Primary completion
Feb 2, 2026
Study completion Feb 2, 2026
Sponsor
- Lead sponsor
- United TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jan 14, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study RIN-PF-301 is designed to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute forced vital capacity (FVC) from baseline to Week 52.
Conditions
- Idiopathic Pulmonary Fibrosis
- Interstitial Lung Disease
Interventions
PlaceboDrug
Placebo administered QID
Inhaled TreprostinilDrug
Inhaled treprostinil (6 mcg/breath) administered QID
Treprostinil Ultrasonic NebulizerDevice
Treprostinil ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Absolute FVC from Baseline to Week 52Time frame: Baseline to Week 52
Locations
98 sites in 3 countries. Site status is shown where the registry gives one.
The University of Alabama at Birmingham
Birmingham, Alabama
Banner University Medical Center-Phoenix
Phoenix, Arizona
Arizona Pulmonary Specialists, Ltd.
Phoenix, Arizona
St. Joseph's Hospital and Medical Center - Norton Thoracic Institute
Phoenix, Arizona
University of Arizona
Tucson, Arizona
UC San Diego Health
La Jolla, California
David Geffen School of Medicine at UCLA
Los Angeles, California
NewportNativeMD, Inc
Newport Beach, California
University of California, Irvine
Orange, California
Palmtree Clinical Research, Inc.
Palm Springs, California
UC Davis Health Medical Center
Sacramento, California
University of California - San Francisco
San Francisco, California
Stanford University Medical Center
Stanford, California
National Jewish Health
Denver, Colorado
St. Francis Sleep Allergy & Lung Institute
Clearwater, Florida
University of Florida Health at Shands
Gainesville, Florida
Ascension St. Vincent's
Jacksonville, Florida
University of Florida
Jacksonville, Florida
Mayo Clinic Florida
Jacksonville, Florida
Pulmonary Disease Specialists, PA d/b/a PDS Research
Kissimmee, Florida
Central Florida Pulmonary Group, PA
Orlando, Florida
Coastal Pulmonary & Critical Care PLC
St. Petersburg, Florida
University of South Florida Health
Tampa, Florida
Cleveland Clinic Florida
Weston, Florida
Piedmont Healthcare Atlanta
Atlanta, Georgia
Emory University Hospital
Atlanta, Georgia
The Queen's Medical Center
Honolulu, Hawaii
Northwestern Memorial Hospital
Chicago, Illinois
Rush University Medical Center Outpatient Pulmonary Clinic
Chicago, Illinois
Loyola University Medical Center
Maywood, Illinois
Community Health Network
Indianapolis, Indiana
The University of Kansas Medical Center
Kansas City, Kansas
Norton Pulmonary Specialists
Louisville, Kentucky
University of Louisville
Louisville, Kentucky
LSU Health Sciences Center New Orleans
New Orleans, Louisiana
Tulane University Medical Center
New Orleans, Louisiana
LSU Health Science Center Shreveport
Shreveport, Louisiana
Johns Hopkins Asthma & Allergy Center
Baltimore, Maryland
Adventist Healthcare White Oak Medical CEnter
Silver Spring, Maryland
Tufts Medical Center
Boston, Massachusetts
Showing 40 of 98 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.